Takara Bio Inc. Provides Earnings Guidance for the Fiscal Years Ending March 31, 2015, March 31, 2016 and March 31, 2017
August 18, 2014
Share
Takara Bio Inc. provided earnings guidance for the fiscal years ending March 31, 2015, March 31, 2016 and March 31, 2017. For the fiscal year ending March 31, 2015, the company expects net sales of JPY 25,200 million, operating income of JPY 2,000 million and net income of JPY 1,480 million.
For the fiscal year ending March 31, 2016, the company expects net sales of JPY 26,500 million, operating income of JPY 2,100 million and net income of JPY 1,500 million.
For the fiscal year ending March 31, 2017, the company expects net sales of JPY 28,000 million, operating income of JPY 2,250 million and net income of JPY 1,550 million.
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
TAKARA BIO INC. 
